Shree Ganesh Remedies Ltd Falls to 52-Week Low Amidst Continued Downtrend

Intraday Price Movement and Market Context

The stock opened with a gap down of 7.32% and further declined to an intraday low of Rs.381.1, representing a drop of 9.92% from the previous close. This decline followed two consecutive days of gains, signalling a reversal in short-term trend. The day’s performance saw Shree Ganesh Remedies underperform its Pharmaceuticals & Biotechnology sector by 3.88%, while the broader Sensex index recovered from an initial negative opening to close 0.19% higher at 81,693.84 points.

Despite the overall market resilience, Shree Ganesh Remedies remains under pressure, trading below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – indicating a sustained bearish trend. The Sensex itself is trading below its 50-day moving average, though the 50DMA remains above the 200DMA, suggesting mixed signals for the broader market.

Performance Over the Past Year

Over the last 12 months, Shree Ganesh Remedies has recorded a substantial decline of 38.10%, significantly underperforming the Sensex, which posted a positive return of 8.40% during the same period. The stock’s 52-week high was Rs.950, highlighting the steep erosion in value over the year. This underperformance is also reflected in the BSE500 index comparison, where the stock generated negative returns of 37.95% against the index’s 8.45% gain.

Financial Results and Profitability Trends

The company’s recent financial disclosures have highlighted a decline in key metrics. Net sales fell by 21.96% in the December 2025 quarter, contributing to a series of four consecutive quarters of negative results. Profit after tax (PAT) for the quarter stood at Rs.3.09 crores, down 43.0% year-on-year. Interest expenses for the nine-month period increased by 49.44% to Rs.2.69 crores, indicating rising financing costs.

Return on Capital Employed (ROCE) for the half-year was recorded at 16.18%, the lowest level observed recently, while Return on Equity (ROE) stood at 11.8%, reflecting moderate profitability relative to shareholder funds. Despite these challenges, the company maintains a low Debt to EBITDA ratio of 0.47 times, suggesting a manageable debt burden and an ability to service its obligations.

Market Capitalisation and Institutional Holding

Shree Ganesh Remedies holds a Market Cap Grade of 4, indicating a mid-sized market capitalisation within its sector. Notably, domestic mutual funds hold no stake in the company, which may reflect limited institutional confidence or a cautious stance given the recent financial performance and valuation concerns. The company’s Mojo Score is 23.0, with a Mojo Grade of Strong Sell as of 12 January 2026, downgraded from Sell, underscoring the cautious market sentiment.

Valuation and Peer Comparison

The stock currently trades at a Price to Book Value of 3.5, which is considered fair but at a discount relative to its peers’ historical averages. This valuation reflects the market’s assessment of the company’s earnings decline and growth prospects. Over the past year, profits have contracted by 37.7%, aligning closely with the stock’s negative return, indicating that earnings deterioration has been a key driver of the share price decline.

Sector and Market Environment

The Pharmaceuticals & Biotechnology sector has experienced mixed performance, with some indices such as NIFTY MEDIA and NIFTY REALTY hitting new 52-week lows today. While mega-cap stocks are leading the broader market gains, mid and small-cap stocks like Shree Ganesh Remedies have faced headwinds. The sector’s overall trend and the company’s position below all major moving averages suggest continued pressure on the stock price.

Summary of Key Metrics

To summarise, Shree Ganesh Remedies Ltd’s stock has declined to Rs.381.1, its lowest level in 52 weeks, reflecting a combination of falling sales, reduced profitability, and cautious market sentiment. The company’s financial ratios indicate a fair valuation but highlight challenges in earnings growth and margin stability. Institutional absence and a strong sell rating further illustrate the current market stance on the stock.

Conclusion

The stock’s recent price action and financial disclosures provide a comprehensive picture of the pressures facing Shree Ganesh Remedies Ltd. While the company maintains a manageable debt profile and some valuation support, the sustained decline in sales and profits has weighed heavily on investor confidence, culminating in the fresh 52-week low. The broader market’s mixed signals and sectoral challenges add to the complexity of the stock’s current position.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →